



UNIVERSITI PUTRA MALAYSIA

**IDENTIFICATION AND CHARACTERIZATION OF A NOVEL ANTI-VIRAL
PEPTIDE AGAINST AVIAN INFLUENZA VIRUS H9N2**

MOHAMED RAJIK

FBSB 2009 18



**IDENTIFICATION AND CHARACTERIZATION OF A NOVEL ANTI-VIRAL
PEPTIDE AGAINST AVIAN INFLUENZA VIRUS H9N2**

By

MOHAMED RAJIK

**Thesis Submitted to the School of Graduate Studies, Universiti Putra Malaysia, in
Fulfilment of the Requirements for the Degree of Doctor of Philosophy**

July 2009



Abstract of thesis presented to the Senate of Universiti Putra Malaysia in fulfillment of the requirements for the degree of Doctor of Philosophy

IDENTIFICATION AND CHARACTERIZATION OF A NOVEL ANTI-VIRAL PEPTIDE AGAINST AVIAN INFLUENZA VIRUS H9N2

By

Mohamed Rajik

July 2009

Chairman: Professor Datin Paduka Khatijah Mohd. Yusoff, PhD

Faculty: Biotechnology and Biomolecular Sciences

Avian influenza viruses (AIV) are major cause of morbidity and mortality in the world. It is the causative agent of the most dangerous disease, called bird flu in common terms, among poultries. This virus belongs to the family of *Orthomyxoviridae* which contains two genera, influenza A & B and influenza C. Although avian influenza A viruses do not usually infect humans, several instances of human infections and outbreaks have been reported. Spanish flu, the well known influenza pandemic of 1918, is thought to have killed more than 50 million people worldwide. Although vaccination is the primary strategy for the control of infection, the antiviral drugs play an important role in the control of illness and transmission. Two classes of antiviral drugs are recommended for the treatment of influenza infection. They are adamantane derivatives (amantadine and rimantadine) and neuraminidase inhibitors (NAIs; zanamivir and oseltamivir). The rate of adamantane resistance has increased significantly from below 2% to an alarming 92.3% in recent years. Few viruses with altered susceptibility to NAIs have also been



isolated from the infected people. Several recent H5N1 influenza isolates recovered from the patients showed resistance to both classes of antiviral drugs. The increasing appearance of resistant strains of influenza virus and side effects of the currently available chemotherapeutic agents emphasises our need to identify new antiviral drugs.

In order to identify novel antiviral drugs, phage display library was utilised in this study. They were biopanned against the purified avian influenza virus H9N2. After four rounds of biopanning, four unique recombinant fusion phages bearing different peptide sequences were isolated. Their binding specificity was confirmed by modified phage-ELISA method. Among the four peptides, the peptide denoting the sequence NDFRSKT (P1) was taken into account for further analysis as it showed a high percentage of presence after the fourth round of panning and good inhibitory properties.

The *in vitro* inhibitory properties of the fusion phages were proved by the ability of the phage molecules to stop the multiplication of the virus in MDCK cell lines whereas, the *in ovo* inhibition ability of both peptides and fusion phages were assessed using the 9 days old embryonated chicken eggs. The antiviral molecule's ability to inhibit the hemagglutination activity and neuraminidase (NA) activity were also investigated using conventional hemagglutination inhibition test and neuraminidase inhibition test respectively. They were able to inhibit the HA activity but failed to inhibit the neuraminidase activity completely. The antibody-phage competition assay showed that the peptide molecule share some common epitopes of the viral surface proteins for their binding site. In order to investigate the *in vivo* binding ability of the molecules inside a



cellular environment and to identify the binding domain on the viral proteins, the peptide and virus surface glycoproteins interaction were analysed by the yeast two-hybrid system. The results showed that the C-terminal region of the HA protein was responsible for the interaction with the peptide. This was further confirmed by the co-immunoprecipitation experiment.

To understand the mechanism of the drug action, the effect of drug on the viral attachment and the viral entry to the host cell (MDCK cells) was studied by fluorescence microscopy and flow cytometry. The study revealed that the peptides prevent the attachment of the virus to the host cells, confirming the result of earlier haemagglutination inhibition experiment. Besides, it was also found that the peptides inhibit the early gene expression. But the peptides do not have any effect on preventing the entry of the virus molecules.

In summary, the current study had identified a novel antiviral peptide which inhibits the AIV H9N2 multiplication *in ovo* and *in vitro*, by binding the HA. This peptide prevents the attachment of the virus to the host cells thereby preventing its internalisation and early protein expressions. These new antiviral molecules may have the potential to control and treat the avian influenza virus infected individuals.



Abstrak tesis yan dikemukakan kepada Senat Universiti Putra Malaysia sebagai memenuhi keperluan untuk ijazah Doktor Falsafah

PENGENALPASTIAN DAN PENCIRIAN PEPTIDA ANTIVIRUS TERHADAP VIRUS INFLUENZA BURUNG H9N2

Oleh

Mohamed Rajik

November 2008

Pengerusi : Professor Datin Paduka Khatijah Mohd. Yusoff, PhD

Fakulti : Bioteknologi dan Sains Biomolekul

Virus influenza burung (AIV) adalah antara penyebab utama penyakit dan kematian spesies burung di dunia. Ia merupakan agen penyebab kebanyakan penyakit berbahaya yang lazimnya dikenali sebagai selsema burung di kalangan ternakan burung. Virus ini adalah dari keluarga *Orthomyxoviridae* yang terdiri daripada dua genera, influenza A & B dan influenza C. Walaupun virus-virus influenza A burung biasanya tidak menjangkiti manusia, terdapat beberapa kes wabak dan jangkitan manusia telah dilaporkan. 'Spanish flu', suatu pandemik influenza pada tahun 1918 yang dimaklumi ramai, dikatakan telah mengorbankan lebih 50 juta orang. Sungguhpun langkah pengvaksinasi merupakan strategi utama bagi pengawalan jangkitan, antivirus dalam bentuk dadah memainkan peranan penting dalam pengawalan penyakit dan penyebaran virus.

Dua kelas dadah antivirus telah disyorkan bagi merawat jangkitan influenza. Mereka adalah terbitan dadah kelas adamantine (amantadine dan rimantadine) dan perencat neuraminidase (NAIs; zanamivir dan oseltamivir). Kadar kerintangan terhadap adamantine di Amerika Syarikat sahaja telah meningkat dari bawah paras 2% kepada nilai amaran iaitu 92.3% beberapa tahun



kebelakangan ini. Sekelompok virus dengan kadar keberkesanan terhadap NAIs telah diperolehi. Beberapa pemencilan influenza baru daripada pesakit jangkitan influenza H5N1 didapati mempamerkan kerintangan terhadap kedua-dua kelas dadah antivirus.

Peningkatan kehadiran strain-strain virus influenza dengan daya kerintangan serta kesan sampingan yang ada menekankan keperluan kita untuk mengenalpasti dadah-dadah antivirus yang baru. Dalam usaha mengenalpasti dadah-dadah antivirus novel, 'phage display library' telah digunakan dalam kajian ini. Mereka telah di'*biopanned*' ke atas virus influenza burung H9N2 yang telah dituliskan. Selepas empat kitaran 'biopanning', empat peptida telah dipencilkan. Ketepatan ikatan mereka telah dipastikan menggunakan kaedah 'phage-ELISA' yang telah diubahsuai. Antara empat peptida tersebut, peptida yang membawa jujukan NDFRSKTC (P1) telah dipilih untuk analisis seterusnya kerana ia menunjukkan kadar kehadiran yang tinggi selepas kitaran keempat '*panning*' di samping mempunyai ciri-ciri perencat yang baik.

Kebolehan merencat secara *in vitro* oleh peptida-peptida dan 'fusion phages' telah dianalisa berdasarkan keupayaan faj atau molekul peptida untuk menyekat pembiakan virus di dalam sel MDCK sementara keupayaan merencat peptida oleh 'fusion phage' secara *in ovo* adalah menggunakan telur ayam berembrio berusia 9 hari. Keupayaan molekul antivirus untuk merencat aktiviti hemaglutinasi dan 'neuraminidase' NA juga telah dikaji masing-masing menggunakan ujian perencatan hemaglutinasi dan ujian perencatan 'neuraminidase' konservatif. Ujian-ujian tersebut berjaya menunjukkan kesan perencatan aktiviti HA tetapi gagal untuk merencat aktiviti 'neuraminidase' secara keseluruhannya.

'Antibody-phage competition assay' menunjukkan bahawa molekul peptida berkongsi beberapa epitop lazim pada protein permukaan virus sebagai tapak pengikatannya. Bagi mengkaji keupayaan pengikatan secara *in vivo* molekul-molekul tersebut dalam persekitaran sel, interaksi antara peptida dan glikoprotein permukaan virus telah dianalisa menggunakan sistem 'yeast two-hybrid'. Kawasan hujung C pada protein HA didapati berupaya mengikat peptida tersebut sementara protein NA menunjukkan interaksi yang lemah terhadap peptida. Ini telah dipastikan lagi melalui eksperimen 'co-immunoprecipitation'.

Untuk memahami mekanisme dadah dengan lebih mendalam, efek dadah tersebut terhadap pelekatan dan penembusan virus kedalam sel his telah dikaji mnggunakan kaedah mikroskop fluoresen dan "cytometry". Kajian ini menunjukkan bahawa peptide-peptida ini mengelakkan pelekatan virus kepada sel hos, sekaligus mengesahkan hasil kajian eksperimen perencatan hemaglutinasi. Lagipun, peptide-peptida tersebut telah didapati boleh merencat ekspresi gen awal.

Namun demikian, mereka tak mempunyai sebarang efek bagi mengelakkkkan kemasukkan molekul-molekul virus. Kesimpulannya, kajian ini telah mengenalpasti satu peptida antivirus novel yang berupaya merencat pembiakan AIV H9N2 secara *in ovo* dan *in vitro*, melalui pengikatan tapak hujung C pada protein HA. Peptida ini mengelakkan pelekatan virus pada sel hos, sekaligus mencegah penembusan serta ekspresi protein awal virus. Molekul-molekul antivirus baru ini mungkin berpotensi untuk mengawal dan merawat pesakit jangkitan virus influenza burung.



ACKNOWLEDGEMENTS

Thanks to my mother and father for giving me the gift of life and the positive values they taught me as a child.

This is to praise God and acknowledge all the great scientists throughout time and living today that have given our world the direction and insights for living life, as it was intended, in peace and harmony.

My most sincere gratitude to my supervisors, Professor Datin Paduka Dr. Khatijah Mohd. Yusoff, Associate Professor Dr. Abdul Rahman Omar, Professor Dr. Aini Ideris and Dr. Sharifah Syed Hassan for the opportunity they gave me, their invaluable guidance, careful supervision and trust on my abilities throughout the study.

My special thanks to Dr. Fatemeh Jahanshiri for her guidance in my professional and personal life and also for being with me during my stressful moments. This also extends to my brother Mohamed Asik, my sister Nashiha Farveen and my friend Hamidah for their supportive role in my personal life.

I appreciate the friendship and assistance from all my lab mates and friends: Abu, Andrew, Carolin, Erin, Farid, Halimi, Hamzah, Hassan, Hidayah, Ho, Jeff, Kah Fai, Khalid, Kie Hie, Lai, Max, MdRos, Naghmeh, Nambi, Nicole, Rajan, Dr. Raha Raus, Pn. Rodiah, Sameera, Sara, Senthil Ramachandran, Sim, Siva, Swee Tin, Thong Chuan,



Dr. Varma, Dr. Vasu and all my admirers. You guys made my life more colorful.
Thanks!

My special thanks also goes to the millions of Malaysian citizens who made this study possible through their tax, for Ministry of Science, Technology and Innovation of Malaysia for the IRPA grant and GSO of UPM for providing me financial assistance through GRF and GRA.

Last, but not least, thanks to my hero Thomas Alva Edison for inspiring me to keep striving to help achieve the impossible dream of invention and innovation with peace and harmony for all of us.



I certify that a Thesis Examination Committee has met on 14 July 2009 to conduct the final examination of Mohamed Rajik on his thesis entitled “Identification and Characterization of a Novel Anti-Viral Peptide Against Avian Influenza Virus H9N2” in accordance with the Universities and University Colleges Act 1971 and the Constitution of the Universiti Putra Malaysia [P.U.(A) 106] 15 March 1998. The Committee recommends that the student be awarded the Doctor of Philosophy.

Members of the Examination Committee were as follows:

Norhani Abdullah, PhD

Professor
Faculty of Biotechnology and Biomolecular sciences
Universiti Putra Malaysia
(Chairman)

Raha Abdul Rahim, PhD

Professor
Faculty of Biotechnology and Biomolecular sciences
Universiti Putra Malaysia
(Internal Examiner)

Raja Noor Zaliha Raja Abdul Rahman, PhD

Professor
Faculty of Biotechnology and Biomolecular sciences
Universiti Putra Malaysia
(Internal Examiner)

Ruben Omar Donis, PhD

Lecturer
Molecular Virology and Vaccines Branch Influenza Division
CCID Centers for Disease Control and Prevention
United States of America
(External Examiner)

BUJANG KIM HUAT, PhD

Professor and Deputy Dean
School of Graduate Studies
Universiti Putra Malaysia

Date: 15 July 2009



The thesis submitted to the senate of Universiti Putra Malaysia and has been accepted as fulfilment of the requirement for the degree of Doctor of Philosophy. The members of the Supervisory Committee were as follows:

Datin Paduka Khatijah Mohd. Yusoff, PhD

Professor

Faculty of Biotechnology and Biomolecular Sciences

Universiti Putra Malaysia

(Chairman)

Abdul Rahman Omar, PhD

Associate Professor

Faculty of Veterinary Medicine

Universiti Putra Malaysia

(Member)

Sharifah Syed Hassan, PhD

Associate Professor

School of Medical and Health Sciences

Monash University Malaysia

(Member)

HASANAH MOHD. GHAZALI, PhD

Professor and Dean

School of Graduate Studies

Universiti Putra Malaysia

Date: 17 July 2009



DECLARATION

I hereby declare that the thesis is based on my original work except for quotations and citations which have been duly acknowledged. I also declare that it has not been previously or concurrently submitted for any other degree at UPM or other institutions.

MOHAMED RAJIK

Date:



TABLE OF CONTENTS

	Page
ABSTRACT	ii
ABSTRAK	v
ACKNOWLEDGEMENTS	viii
APPROVAL	x
DECLARATION	xii
LIST OF TABLES	xvii
LIST OF FIGURES	xviii
LIST OF ABBREVIATIONS	xx
CHAPTER	
1. INTRODUCTION	1
2. LITERATURE REVIEW	6
2.1 Avian Influenza Virus	6
2.1.1 Classification	6
2.1.2 Characteristics of influenza viruses	7
2.1.3 Structure of the virus	7
2.1.4 Proteins of the avian influenza virus	10
2.1.5 Replication of the virus	13
2.1.6 Genetics of the virus	15
2.1.7 Inhibitors of viral replication	17
2.2 Phage display	18
2.2.1 Biology of filamentous bacteriophage M13	18
2.2.2 Phage display technology	20
2.2.3 Applications of phage display technology	23
2.2.4 Disulfide constrained cyclic peptides	29
2.3 Protein-protein interactions	30
2.3.1 Yeast two-hybrid system	31
2.3.2 Co-immunoprecipitation	34
2.4 Flow cytometry	35
2.4.1 Analysis of virus infected cells	36
3. MATERIALS AND METHODS	39
3.1 General procedures	39
3.1.1 Propagation and purification of AIV	39
3.1.2 Haemagglutination (HA) test	41
3.1.3 The Bradford assay	41
3.1.4 Small scale phage propagation	42
3.1.5 Phage titration	43
3.1.6 Phage single stranded DNA (ssDNA) extraction	44
3.1.7 Sequencing of ssDNA	44



3.1.8	Viral RNA extraction	45
3.1.9	Raising polyclonal antibody against AIV H9N2	45
3.1.10	Monitoring the titer of polyclonal antibodies by ELISA	46
3.1.11	Cytotoxicity test by MTT assay	46
3.2	Selection of peptides	47
3.2.1	Biopanning of purified AIV	47
3.2.2	Assaying selected peptides for target binding by ELISA	48
3.3	Characterisation of the peptides and fusion phages	49
3.3.1	Inhibition of haemagglutination activity	49
3.3.2	Inhibition of neuraminidase activity	49
3.3.3	Inhibition of hemolytic activity	49
3.3.4	Antibody-phage competition assay	50
3.3.5	Determination of IC ₅₀	50
3.3.6	Inhibition of AIV H9N2 propagation in embryonated chicken eggs	51
3.4	Construction of recombinant plasmids	52
3.4.1	Amplification of <i>HA_t</i> and <i>NA</i> genes	52
3.4.2	Amplification of peptide (<i>PI</i>) gene	54
3.4.3	Directional ligation	55
3.5	Transformation into <i>E.coli</i>	56
3.5.1	Preparation of competent <i>E.coli</i> cells	56
3.5.2	Transformation	57
3.6	Identification of recombinant plasmids	57
3.6.1	Plasmid extraction	57
3.6.2	Confirmation of the clones by double digestion	58
3.6.3	DNA sequencing	59
3.7	Yeast transformation	59
3.7.1	Preparation of denatured salmon sperm DNA	59
3.7.2	Preparation of yeast competent cells and transformation	60
3.8	Interaction study	61
3.8.1	Quantitative β-galactosidase assay	61
3.9	<i>In vitro</i> transcription and translation	62
3.9.1	Construction of recombinant pCITE2a	62
3.9.2	PCR to amplify <i>HA_t</i> , <i>NA</i> and <i>PI</i> genes	62
3.9.3	Directional ligation	63
3.9.4	<i>In vitro</i> transcription and translation	65
3.9.5	SDS-PAGE	65
3.9.6	Western blotting	67
3.10	Co-immunoprecipitation of <i>in vitro</i> translated products	68
3.11	Fluorescein isothiocyanate (FITC) labeling	69
3.12	Immunofluorescence assay	69
3.13	Flow cytometry analysis	70
3.14	Cell penetrating ability of the anti-viral peptides	70
3.15	Statistical analysis	71



4. RESULTS	72
4.1 Selection of peptides against AIV H9N2	72
4.2 Characterisation of fusion phages and peptides	74
4.2.1 Determination of binding ability of the phages	75
4.2.2 Inhibition of haemagglutination activity	77
4.2.3 Inhibition of neuraminidase activity	79
4.2.4 Inhibition of hemolytic activity	81
4.2.5 Antibody-phage competition assay	81
4.3 Antiviral activities of the peptides and fusion phages	86
4.3.1 Antiviral activity of cyclic and linear peptides <i>in ovo</i>	86
4.3.2 Antiviral activity of fusion phages (FP-P1) <i>in ovo</i>	90
4.3.3 Antiviral activity of fusion phages (FP-P1) <i>in vitro</i>	94
4.4 Virus-peptide interaction study by yeast two hybrid assay	98
4.4.1 Amplification and cloning of <i>HA_t</i> and <i>NA</i> gene	99
4.4.2 Amplification and cloning of <i>P1</i> gene	102
4.4.3 Background study and interaction between the <i>HA_t</i> / <i>NA</i> protein and <i>P1</i> peptide	104
4.5 Virus-Peptide interaction study by Co-immunoprecipitation	106
4.5.1 Construction of recombinant pCITE-2a	107
4.5.2 <i>In vitro</i> transcription and translation of <i>P1</i> peptide, <i>HA_t</i> and <i>NA</i> proteins	109
4.5.3 Interaction of <i>HA_t</i> protein with <i>P1</i> peptide	111
4.6 Mechanism of action of the anti-viral peptide	114
4.6.1 Effect of anti-viral peptide <i>P1</i> on viral attachment	114
4.6.2 Effect of anti-viral peptide <i>P1</i> on viral entry	117
4.6.3 Effect of anti-viral peptide <i>P1</i> on early gene expression	119
4.7 Cell penetrating ability of the peptide	121
5. DISCUSSION	123
5.1 Selection of peptides against AIV H9N2	125
5.2 Characterisation of antiviral molecules	128
5.3 Antiviral activity of peptides and fusion phages	133
5.4 Virus-peptide interaction study by yeast two-hybrid system	137
5.5 Virus-peptide interaction study by Co-immunoprecipitation	139
5.6 Mechanism of action of the anti-viral peptide <i>P1</i>	141
6. CONCLUSION AND FUTURE PROSPECTS	144
REFERENCES	146
APPENDICES	166
BIODATA OF THE STUDENT	172
LIST OF PUBLICATIONS	173





LIST OF TABLES

Table		Page
1	Oligonucleotides used to amplify the <i>NA</i> and <i>HA_t</i>	52
2	RT-PCR reaction mix used in the amplification of <i>HA_t</i> and <i>NA</i> genes	53
3	Oligonucleotides used to amplify the <i>P1</i> gene	54
4	PCR reaction components used in the amplification of <i>P1</i> gene	55
5	Oligonucleotides used in the sequencing of the recombinant plasmids	59
6	Oligonucleotides used in the amplification of <i>HA_t</i> , <i>NA</i> and <i>P1</i> genes for cloning into pCITE2a vector	63
7	Oligonucleotides used in sequencing of <i>HA_t</i> , <i>NA</i> and <i>P1</i> genes cloned in pCITE2a vector	64
8	Heptapeptides selected from the phage display library	73
9	Inhibition of the haemagglutination activity	78
10	Inhibition of neuraminidase activity of the virus by linear peptides	80
11	P1: HA _t /NA interactions in the yeast two-hybrid system	105
12	Effect of the peptides on viral attachment to host cells	116



LIST OF FIGURES

Figure		Page
1	Schematic diagram of the virion structure of AIV	8
2	Replication cycle of influenza A virus	14
3	A schematic diagram of biopanning of phage displayed peptide library against a target	21
4	A diagrammatic explanation of yeast two-hybrid system assay	32
5	Binding ability of all four recombinant phages to AIV H9N2	76
6	Rabbit antiserum titers throughout the immunization period	83
7	Antibody-phage competition assay	85
8	Determination of the IC ₅₀ values of the synthetic peptides <i>in ovo</i>	87
9	Inhibition of virus propagation by cyclic and linear peptides <i>in ovo</i>	89
10	IC ₅₀ of fusion phage FP-P1 against virus propagation <i>in ovo</i>	91
11	Anti-viral activity of fusion phages FP-P1 <i>in ovo</i>	93
12	Antiviral activity of the fusion phage <i>in vitro</i>	95
13	Effect of the fusion phage FP-P1 on viral replication <i>in vitro</i>	97
14	Agarose gel electrophoresis of PCR products of HA _t and NA genes	100
15	Agarose gel electrophoresis of cloning and double digestion of HA _t and NA genes	101
16	Agarose gel electrophoresis of RT-PCR, cloning and digestion of P1 gene	103
17	Agarose gel electrophoresis of PCR products of HA _t , NA and P1 genes and digestion of recombinant pC-HA, PC-NA and pH-P1	108



18	Western blotting of <i>in vitro</i> translated P1, HA _t and NA proteins	110
19	Schematic diagram of the Co-Immunoprecipitation method	112
20	Western blot analysis of immunoprecipitated HA _t – P1 complex	113
21	Effect of the peptide P1 on viral entry	118
22	Effect of anti-viral peptide P1 on early gene expression	120



LIST OF ABBREVIATIONS

AD	activation domain
AIV	avian influenza virus
BCP	1-bromo-3-chloro-propane
BCIP	5-bromo-4-chloro-3-indolyl phosphate
BD	binding domain
β -gal	β -galactosidase
bp	base pair
cDNA	complementary deoxyribonucleic acid
ci	curi
CITE	cap-independent translation enhancer
C-terminus	carboxy terminus
dH ₂ O	distilled water
DNA	deoxyribonucleic acid
dNTP	deoxyribonucleotides
DTT	1,4-dithiothritol
EDTA	ethylenediaminetetraacetic acid
ELISA	enzyme-linked immunosorbent assay
GST	glutathione S-transferase
h	hour
HA	Haemagglutinin activity
His	Histidine



kb	kilo base
kDa	kilo Dalton
LB	Luria Bertani
μg	microgram
μl	microlitre
μM	micromolar
mA	milliampere
mRNA	messenger RNA
NBT	nitro blue tetrazolium
NP	nucleocapsid protein
NP40	Nonidet P40
nt	nucleotide
N-terminus	amino terminus
OD	optical density
ORF	open reading frame
PAGE	polyacrylamide gel electrophoresis
pH	<i>puissance hydrogene</i>
PCR	polymerase chain reaction
RBC	red blood cell
RNA	ribonucleic acid
RNase	ribonuclease
rpm	revolutions per minute
RT-PCR	reverse transcriptase-polymerase chain reaction



s	second
SDS	sodium dodecyl sulphate
SV5	simian virus 5
TAE	Tris-acetate – EDTA buffer
TBA	Tris-buffered saline
Taq	<i>Thermus aquaticus</i>
TEMED	tetramethyl ethylenediamine
U	unit
uv	ultraviolet
Vol	volume
w/v	weight/volume
YC	minimal medium for yeast



CHAPTER 1

INTRODUCTION

Avian influenza (AI) is caused by avian influenza virus (AIV) which belongs to the family *Orthomyxoviridae*, genus *Influenza A*. It rapidly infects poultry as well as many species of birds. The viruses are classified into subtypes on the basis of antigenic differences in their surface glycoprotein hemagglutinin (HA/H) and neuraminidase (NA/N). To date, 16 HA subtypes (H1-H16) and 9 NA subtypes (N1-N9) have been recognised (Webster *et al.*, 1992). AIV can also be categorised as high pathogenicity (HP) and low pathogenicity (LP) on the basis of the severity of clinical signs and mortality rates in experimentally inoculated chickens (Swayne *et al.*, 2000). HPAI is in list A disease of the Office International des Epizooties (OIE; <http://www.oie.int>, September 2008).

AIVs occur naturally among birds. Wild birds worldwide carry the viruses in their intestines, but usually do not get sick from them. Domesticated birds may become infected with AIV through direct contact with infected waterfowl or other infected poultry, or through contact with contaminated surfaces (such as dirt or cages) or materials (such as water or feed) (Goldrick and Goetz, 2007).

Infection with AIVs in domestic poultry causes two main forms of disease that are distinguished by low and high extremes of virulence. The “low pathogenic” form may

